CALR and breast carcinoma: In particular, in in vivo experiments, the peptide enhanced the antitumor effect of DOX through the combination of IND, decreased IL‐6 expression, increased CRT and CD4 levels, attenuated tumor‐associated inflammation, and enhanced immunity, which effectively inhibited breast cancer growth.